Biomarkers in Substance Use Disorders
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The prevention and treatment of substance use disorders (SUDs), including addiction, would benefit from having better biomarkers for the classification of patients into categories that are reproducible and have predictive validity. Direct measurement of drugs or their metabolites in various body fluids constitutes a clinically valuable biomarker but one that can only be used to corroborate acute or relatively recent drug use. Thus, there is an urgent need for biomarkers that reflect chronic drug exposure as well as biomarkers that predict or correlate with disease trajectories and treatment responses. Advances in tools and technologies to investigate genetics, epigenetics and epitranscriptomics, and human brain function and neurochemistry (brain imaging tools including EEG) offer unprecedented opportunities for the development of such biomarkers. Progress in this area will not only enhance our ability to screen and treat patients with SUDs but also accelerate research on the neurobiological processes that underlie SUDs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
Self-citationThe Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Self-citationAddiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex
Volkow, N. D. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.3.318 · Cited by 1,240
Self-citationNucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement
Dalley, J. W., Fryer, T. D., Brichard, L., Robinson, E. S. J., Theobald, D. E. H., Lääne, K., Peña, Y., Murphy, E. R., Shah, Y., Probst, K., et al. (2007) · Science · doi:10.1126/science.1137073 · Cited by 1,188
Imaging dopamine's role in drug abuse and addiction
Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R., & Telang, F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.022 · Cited by 988
Self-citationAddiction: Beyond dopamine reward circuitry
Volkow, N. D., Wang, G.-J., Fowler, J. S., Tomasi, D., & Telang, F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010654108 · Cited by 959
Self-citationCell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward
Lobo, M. K., Covington, H. E., Chaudhury, D., Friedman, A. K., Sun, H., Damez-Werno, D., Dietz, D. M., Zaman, S., Koo, J. W., Kennedy, P. J., et al. (2010) · Science · doi:10.1126/science.1188472 · Cited by 880
Neural mechanisms of genetic risk for impulsivity and violence in humans
Meyer-Lindenberg, A., Buckholtz, J. W., Kolachana, B., R. Hariri, A., Pezawas, L., Blasi, G., Wabnitz, A., Honea, R., Verchinski, B., Callicott, J. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511311103 · Cited by 876
Edenberg, H. J. (2007) · Europe PMC (PubMed Central) · Cited by 767
Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration
Morgan, D., Grant, K. A., Gage, H. D., Mach, R. H., Kaplan, J. R., Prioleau, O., Nader, S. H., Buchheimer, N., Ehrenkaufer, R. L., & Nader, M. A. (2002) · Nature Neuroscience · doi:10.1038/nn798 · Cited by 674
Research works printed but not linked: 1
- Edenberg H. J., 2007, Alcohol Res. Health, 30, 5
Cited by
Candidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Neuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 322
Self-citationSubstance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11
Saunders, J. B. (2017) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000332 · Cited by 173
Resting‐state functional connectivity and nicotine addiction: prospects for biomarker development
Fedota, J. R., & Stein, E. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12882 · Cited by 164
A neuromarker for drug and food craving distinguishes drug users from non-users
Koban, L., Wager, T. D., & Kober, H. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01228-w · Cited by 165
Metadata
- Authors
- Volkow, N. D., Koob, G., & Baler, R.
- Affiliations
- National Institutes of Health (US)
- National Institute on Drug Abuse and ‡National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, United States
- Corresponding author
- Volkow, Nora D
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-03-18
- Volume
- 6
- Issue
- 4
- Pages
- 522-525
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2057763983
- Cited by
- 141
- References
- 41
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 17 · 2023: 8 · 2022: 18 · 2021: 13 · 2020: 11 · 2019: 13 · 2018: 15 · 2017: 10 · 2016: 13 · 2015: 4
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- substance use disorders, addiction, biomarkers, chronic drug exposure, disease trajectories, treatment response prediction, epigenetics, epitranscriptomics, neuroimaging, EEG, neurochemistry
- MeSH terms
- Animals, Humans, Biomarkers, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers in Substance Use Disorders. https://app.cochat.ai/papers/10.1021/acschemneuro.5b00067
- The paper
- Volkow, N. D., Koob, G., & Baler, R. (2015). Biomarkers in Substance Use Disorders. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5b00067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.